<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324922</url>
  </required_header>
  <id_info>
    <org_study_id>27915-B</org_study_id>
    <secondary_id>05-6396-B 01</secondary_id>
    <nct_id>NCT00324922</nct_id>
  </id_info>
  <brief_title>Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus (MRSA) Osteomyelitis (VOTSMO)</brief_title>
  <official_title>A Prospective, Randomized Trial Comparing Vancomycin With Trimethoprim/Sulfamethoxazole for the Treatment of MRSA Osteomyelitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary question of this study is to understand if trimethoprim-sulfamethoxazole
      (TMP-SMX) is as effective as vancomycin for treating methicillin-resistant Staphylococcus
      aureus (MRSA) osteomyelitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of osteomyelitis is hampered by a paucity of evidence from prospective clinical
      trials with randomized treatment arms. Furthermore, previous randomized or observational
      trials have enrolled small numbers of subjects and thus often had non-definitive findings.
      One of the most common causes of osteomyelitis is Staphylococcus aureus. Over the past 10
      years, rates of methicillin-resistant S. aureus (MRSA) have risen dramatically. Vancomycin is
      currently the treatment of choice for treating MRSA. While vancomycin is effective, it is
      only available in intravenous formulation and has renal and bone marrow toxicities. There is
      a critical need for effective, oral, cheap drugs for the treatment of MRSA.
      Trimethoprim-sulfamethoxazole (TMP-SMX) is a drug with several advantageous properties for
      the treatment of MRSA osteomyelitis. To address this question regarding optimal treatment of
      MRSA osteomyelitis, we designed a prospective, randomized trial comparing TMP-SMX with
      vancomycin for the treatment of MRSA osteomyelitis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Osteomyelitis</condition>
  <condition>Methicillin-resistant Staphylococcus Aureus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>trimethoprim-sulfamethoxazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vancomycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole</intervention_name>
    <description>trimethoprim/sulfamethoxazole 320/1600 mg po bid</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin</intervention_name>
    <description>1g iv bid</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Culture-proven MRSA, obtained in operating room or sterile biopsy procedure from bone
             site. The infection and sampling site can either be within bone or a deep soft-tissue
             site that is contiguous with bone; OR radiographic abnormality consistent with
             osteomyelitis in conjunction with a positive blood culture for MRSA.

          2. Surgical debridement of infection site, as needed.

          3. Subject is capable of providing written informed consent.

          4. Subject is at least 18 years of age.

          5. Subject capable of receiving outpatient parenteral therapy for 12 weeks.

        Exclusion Criteria:

          1. Hypersensitivity to TMP-SMX or vancomycin.

          2. S. aureus resistant to TMP-SMX or vancomycin.

          3. Osteomyelitis that develops directly from a chronic, open wound.

          4. Polymicrobial culture(the only exception is if coagulase-negative staphylococcus is
             present in the culture and the clinical assessment is that it is a contaminant).

          5. Subject has a positive pregnancy test at study enrollment.

          6. Convicted felon currently in prison.

          7. Baseline renal or hepatic insufficiency that would preclude administration of study
             drugs.

          8. Active injection drug use without safe conditions to administer intravenous
             antibiotics for 3 months.

          9. Anticipated use of antibiotics for greater than 14 days for an infection other than
             osteomyelitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy H. Dellitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanne Chan, PharmD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Golden, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Bradford Henley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeanne M Marrazzo, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa Taitsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas R Hawn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert D Harrington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UW</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Ramers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2006</study_first_posted>
  <last_update_submitted>July 27, 2009</last_update_submitted>
  <last_update_submitted_qc>July 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Robert Harrington</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Vancomycin</keyword>
  <keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Osteomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

